All I know is the clinical trial switched its status to completed in August. Give it 1.5 months for the database lock and 3.5 months for statistical analysis and unblinding, then Biosplice should've received the top line results in January. Maybe they did receive them and this is the reason why they are 1) cutting staff and clinical programs and 2) generating a new focus on cancer so they can raise even more funds. My bet is lorecivivint failed since we would've heard by now if it had succeeded.
research reports and media, page-2394
-
- There are more pages in this discussion • 1,924 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.010(3.77%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $162.7K | 620.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25008 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 34768 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |